🔎 Trials Near Me

Utama › Leukemia-Limfoma Limfoblastik Sel-T Pendahulu › Texas

Kajian klinikal Leukemia-Limfoma Limfoblastik Sel-T Pendahulu di Texas

8 kajian untuk Leukemia-Limfoma Limfoblastik Sel-T Pendahulu sedang mencari peserta di lokasi di Texas.

Bandar di Texas

Teks kajian rasmi (Bahasa Inggeris)

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

  • MD Anderson Cancer Center, Houston
  • Sarah Cannon Transplant and Cellular Therapy Methodist Hospital, San Antonio
Mengambil pesertaFasa 2
6 Months · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06514794

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

  • MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 1
Sehingga umur 39 · Semua jantina · Dikemas kini 11 Sep 2026 · NCT04972942

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

  • Houston Methodist Hospital, Houston
  • Texas Children's Hospital, Houston
Mengambil pesertaFasa 1
Sehingga umur 75 · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT03081910

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • M D Anderson Cancer Center, Houston
Mengambil pesertaFasa 2
Semua umur · Semua jantina · Dikemas kini 15 Jul 2026 · NCT00501826

A Registry for People With T-cell Lymphoma

  • MD Anderson Cancer Center (Data Collection Only), Houston
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 20 Mei 2026 · NCT05978141

Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

  • Houston Methodist Hospital, Houston
  • Texas Children's Hospital, Houston
Mengambil pesertaFasa 1
Sehingga umur 75 · Semua jantina · Dikemas kini 18 Mei 2026 · NCT07220993

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.